Share: Facebook Twitter LinkedIn
Activity Provided By:

Integritas Communications

Hitting The Bullseye in NSCLC

Access Activity

Overview / Abstract:

Lung cancer is the second most common cancer in both men and women and is the leading cause of cancer-related deaths. The majority of lung cancer cases are categorized as NSCLC, which has a low overall 5-year survival rate, especially when it is diagnosed at advanced, unresectable stages. Recent advances in the treatment landscape have yielded promising improvements in progression-free survival and overall survival; however, outcomes are dependent on numerous factors, including the evaluation of mutational status and prompt implementation of targeted therapeutic strategies. This 4-part CME Snapshot activity has been designed to educate and promote critical thinking through a discussion-based format, with elements of 3D animation. Multidisciplinary expert faculty discuss the appropriate molecular testing techniques to evaluate mutational status and provide practical recommendations for individualized treatment strategies in unresectable EGFR+ NSCLC based on their clinical experience and the latest published clinical evidence.


Sep 24, 2024


Nurse Practitioner , Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Heather Wakelee, MD, FASCO
Professor of Medicine and Chief of the Division of Oncology
Stanford University School of Medicine
Deputy Director, Stanford Cancer Institute
President, International Association for the Study of Lung Cancer (IASLC)
Stanford, California
Gerald Berry, MD
Richard Kempson, MD Professor of Surgical Pathology
Stanford University School of Medicine
Director of Cardiac and Pulmonary Pathology
Stanford Medicine
Stanford, California

Stefanie Houseknecht, PharmD, BCOP
Clinical Pharmacy Specialist, Thoracic Oncology
The Johns Hopkins Hospital and Bayview Medical Center
Baltimore, Maryland

Anjali Sibley MD, MPH
Hematologist & Medical Oncologist
Medical Director, Stanford Emeryville Cancer Center
Stanford Healthcare
Emeryville, California

Sponsors / Supporters / Grant Providers

This activity is provided by Global Education Group. (ACCME Credit)

This activity is jointly provided by Global Education Group and Integritas Communications. (AANP & ACPE Credit)

This activity is supported by an educational grant from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Keywords / Search Terms

Integritas Communications lung cancer, oncology, NSCLC, EGFR Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map